Tag: AMyris

Amyris executes strategic supply agreements with Raizen

Amyris executes strategic supply agreements with Raizen

May 21, 2019 |

In California, Amyris announced the execution of strategic supply agreements with Raizen for the supply of sugar, energy and other utilities to its new planned production plant co-located with Raizen’s Barra Mill at Barra Bonita, Brazil. In addition to the supply agreements, the companies entered into an arrangement to establish the basis for the creation […]

Read More

Amyris receives first cash payment of $10 million for reaching cannabinoid milestones

Amyris receives first cash payment of $10 million for reaching cannabinoid milestones

May 20, 2019 |

In California, Amyris reported that it has received from its cannabinoid partner, LAVVAN, a first cash payment of $10 million for having successfully delivered on its first major collaboration milestone as announced on March 29, 2019. “We are very pleased with the continued strong execution of our business strategy and the performance of our technology […]

Read More

Amyris Completes Sale of Vitamin E Royalty to DSM

Amyris Completes Sale of Vitamin E Royalty to DSM

April 21, 2019 |

In California, Amyris, Inc. sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility […]

Read More

Learnings from the Earnings – Who’s Up? Who’s Down?

Learnings from the Earnings – Who’s Up? Who’s Down?

March 23, 2019 |

The lucky 13 – with spring comes a sense of renewal and this season these lucky 13 bioeconomy bellwethers recently shared their 2018 and Q4 earnings to reveal uncertainties with trade wars, especially between the U.S. and China, some deals that fell through impacting losses, and pricing issues. But all is not lost as there […]

Read More

Amyris part of major NIH project to bioengineer vaccine adjuvants alternative

Amyris part of major NIH project to bioengineer vaccine adjuvants alternative

February 12, 2019 |

In California, Amyris, Inc. and IDRI (Infectious Disease Research Institute announced IDRI’s receipt of a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover sustainable alternatives to shark squalene to use as vaccine adjuvants (grant number: R01AI135673). Funding is provided by a […]

Read More

Amyris seals $255 million development and commercialization deal for cannabinoids

Amyris seals $255 million development and commercialization deal for cannabinoids

February 6, 2019 |

In California, Amyris announced that it has signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. The $255 million in payments include an upfront payment and the remainder are linked to milestones […]

Read More

Amyris signs with Chinese company nutritional product royalty arrangement

Amyris signs with Chinese company nutritional product royalty arrangement

December 31, 2018 |

In California, Amyris, Inc. announced that it has signed a long-term agreement with Xinfu of China for a significant initial payment and a long-term minimum annual share of an existing nutritional product royalty arrangement. This agreement enables Amyris to monetize a portion of the long-term royalty opportunity for this product upfront to better manage volatility […]

Read More

Amyris teams with Spanish fermentation company to expand production

Amyris teams with Spanish fermentation company to expand production

December 10, 2018 |

In California, Amyris announced that it has executed an expanded agreement for its existing production contract with ADL Bionatur Solutions, through its fermentation division ADL Biopharma. ADL Bionatur, a European leader in research and development of health products, services and industrial fermentation production, provides cost effective, contract manufacturing capabilities. This marks the second expansion of […]

Read More

Amyris gets green light for zero-calorie sweetener made from sugarcane

Amyris gets green light for zero-calorie sweetener made from sugarcane

September 3, 2018 |

In California, Amyris, Inc. announced that its zero-calorie sweetener made from sugarcane has received designation as GRAS (Generally Recognized as Safe) by an independent expert panel. This designation is based on FDA requirements and allows Amyris to begin commercially selling its new, natural, zero-calorie sweetener. Amyris plans to commercially launch its sweetener during the fourth […]

Read More

Top 10 Transformations – Pivotal Pivots for survival in the bioeconomy

Top 10 Transformations – Pivotal Pivots for survival in the bioeconomy

July 15, 2018 |

We frequently hear that the only constant is change and in today’s bioeconomy world, we see this lived out all the time. Companies come and go but some evolve, transform, and change. Today we focus on some of these pivotal pivots and the transformations with these leaders who live and breathe change to survive. Some […]

Read More